drugset / Trial / NCT04410887
Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to compare the safety and efficacy of PIPAC+SOX+OLAPARIB for locally-invaded-gastric cancer (LIGC) patients in China. To obtain preliminary results for designing a new phase II/III randomized controlled trial.
Timeline
- Start
- 2020-12
- Primary completion
- 2021-12
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Other |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg/m2 | Oral |